Samsung BioLogics Co., Ltd.
South Korean contract drug maker that changed the accounting treatment of an affiliate, inflating net profit by 4.5 trillion won prior to IPO.
- Entity Name: Samsung BioLogics Co., Ltd.
- Country of Domicile: KR
- Listing & Ticker: KRX (207940).
- CIK / LEI Identifier: Unregistered.
- Industry Classification: Pharmaceutical Preparations (SIC 2834).
- Cumulative Overstatement: $3.8B across 1 enforcement episode(s).
- Assessed Penalties: $7.0M.
PRIMARY ENFORCEMENT CASES INVOLVING SAMSUNG BIOLOGICS CO., LTD.
1 CASE DOSSIERS| Case Title | Status | Primary Scheme | Overstatement | Total Penalties | Action Date |
|---|---|---|---|---|---|
| Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation | Adjudicated | acquisition accounting abuse | $3.8B | $7.0M | September 20, 2020 |
FORENSIC PROFILE: SAMSUNG BIOLOGICS: 4.5 TRILLION WON ACQUISITION ACCOUNTING INFLATION
FULL CASE DOSSIER →Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.
The company manipulated its accounting records by executing schemes under acquisition-accounting-abuse. Financial reports filed with market regulators contained material misstatements that distorted true financial condition.
Fraud Window: January 1, 2018 to December 31, 2020 • Primary Regulator: Financial Supervisory Service (South Korea) • Auditor: Samjong KPMG
Documented Accounting Irregularities & Regulatory Findings
- ACQUISITION ACCOUNTING ABUSE: Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit.
Primary Public Dockets & Actions
- [ENF-2018-samsung-biologics] Enforcement Action: Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation (September 20, 2020): Opportunistically changed valuation of joint venture affiliate Samsung Bioepis to fair value, manufacturing a 4.5T won net profit. Official Record ↗